The COSTLY-TLR Study1 defines and reports the real-world costs of target lesion revascularisation procedures (TLR) in patients with femoropopliteal in-stent-restenosis and occlusion (ISR) following stenting, from a healthcare payer’s perspective.
References:
1. Saratzis et al. COST Analysis of Target Lesion Revascularisation in Patients With Femoropopliteal In-Stent Restenosis or Occlusion: The COSTLY-TLR Study. Eur J Vasc Endovasc Surg. 2024 Feb 6:S1078-5884(24)00160-6. doi: 10.1016/j.ejvs.2024.02.001. Epub ahead of print. PMID: 38331163.
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.